Press release: phase III MARIPOSA study meets its primary endpoints. First line amivantamab plus lazertinib superior to osimertinib in #EGFR mutant NSCLC (del19, L858R) with significant and "meaningful" improvement in PFS (and OS trend). Await #ESMO23! prnewswire.com/news-releases/…

Amazing news. Looking forward to #ESMO23. I suspect this strategy will become widely used.

LIBRETTO 431 abstract #ESMO23

Disappointing 🥲🥲🥲🥲

ESMO LBAs! -ALINA adj alectinib HR DFS .24 -PAPILLON 1L Ct-amivantamab vs Ct in EGFR Ex20 HR PFS .40 -LIBRETTO-431 1L selperca vs Ct-IO in RET+ HR PFS .46 -CM77T periop nivo HR EFS .58 -MARIPOSA 1L ami-laz vs osi in EGFRmut HR PFS .70 -TROPION 2L+ Dato-DXd vs docetaxel HR PFS .75

Impressive waterfall plot for #NSCLC KRASG12C PDL1 > 50% treated in first line by pembrolizumab + Adagrasib. RR 63%. Manageable liver toxicity. #ESMO23 OncoAlert

🤔FLAURA-2 CNS results #ESMO23 Osi is supposed to have good brain penetrance. Addition of chemo increases brain RR in EGFR pts 🙋Is it because it increases brain delivery of osi or it targets osi resistant / persister cells in the brain ? 👍Anyway, impactful data. OncoAlert

#ESMO23 Presidential 1 THE LungCancer story ♥️ - PAPILLON ✅ - ALINA ✅ - LIBRETTO 431 ✅ - CheckMate77L ✅ What else?! 🔥

It's a wrap! #ESMO23 has come to an end. A great conference, with practice changing and exciting new data on #breastcancer, #lungcancer, #bladdercancer, #ProstateCancer, #kidneycancer and #GItumors. Watch the reports from the #high5oncologyTV experts now: high5oncology.tv/esmo-2023/

Estudios de inmunoterapia en cáncer publicados en el NEJM.

Moral support has poured in for Dr. Krittai Tanasombatkul, with his hashtag “Don’t give up” (#สู้ดิวะ) top trending on X today, after he updated his condition as he suffers with his terminal lung cancer, saying he may succumb to the disease in the middle of December. Read more:

Dr. Tanasombatkul, a 29 y/o doctor with stage 4 #lungcancer shares that he does not have much time left. He wants others to know “Everyone can get this bc the world has become abnormal, with air & water pollution and various forms of radiation and our genes are ready to mutate"

💥Hot off the press👉 Pleased to share our paper 👉Association between treatment and improvements in overall survival of patients with advanced/metastatic non–small cell lung cancer since 2011: A study in the United States, Canada, & Germany using retrospective real-world

FLAURA2 now NEJM. Phase III trial of first-line osimertinib alone or with chemotherapy for #EGFR NSCLC (n=557). Adding chemotherapy significantly improved PFS (HR 0.62) and mDOR (15.3m vs 24m), but at the cost of added toxicity (and q3w infusions). nejm.org/doi/full/10.10…

FLAURA2 Editorial NEJM from Drs. Yi-long Wu and Qing Zhou. Do the PFS benefits outweigh the toxicity and need for infusions every 3 weeks? A survey by the Chinese Thoracic Oncology Group of 363 pts showed 73% chose monotherapy even with 9m PFS benefit (79% who had prior chemo).

Cuando no estás enfermo, la necesidad no parece tan urgente. En curva de la derecha la supervivencia global de acuerdo a la aprobación EMA: 85% vivos a 3 años frente a situación en España: 66% vivos en 3 años. Por favor que nuestros "expertos" expliquen qué no entienden.

EXCLAIM2 trial: mobicertinib vs CT in 1st line EGFRex20ins 🫁NSCLC is ⛔️. Amivantamab + CT potential🦋new SoC in this population. However our hopes in new EGFRex20ins TKI with promising efficacy and better toxicity profile, and perhaps better icRR 🧠➡️relevant point!! #ESMOAsia23

🚨Disappointing results!!   Sanofi announces CARMEN-LC03 trial failed to improve PFS in previously treated pts with metastatic NSq NSCLC with high levels of CEACAM5 ⚒️The tusamitamab ravtansine clinical development program will be discontinued globenewswire.com/news-release/2…

What a disappointment!!!Complexity of ADCs mechanisms of action and need to review selection of patients with fresh tumor biopsy ?

Impact of Multidisciplinary Cancer Conferences on Overall Survival: A Meta-Analysis academic.oup.com/jnci/article-a…